Compare REX AI Equity Premium Income ETF (AIPI) vs Cardinal Health Inc (CAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Cardinal Health Inc — how do they compare? REX AI Equity Premium Income ETF trades at $36.23, while Cardinal Health Inc trades at $238.08 (market cap $56.14B). The key difference: Cardinal Health Inc pays a 0.85% dividend while REX AI Equity Premium Income ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | CAH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $239.71 |
52-Week Low | $32.45 | $146.04 |
Market Cap | — | $56.14B |
Enterprise Value | — | $61.12B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
Cardinal Health (CAH) trades at $239.71, up 0.32% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats, including Q1 2026 EPS of $3.17 beating estimates of $2.79. Revenue reached $222.58B in 2025 with net income of $1.56B. Technical indicators are bullish, with the current price above key support levels. Analysts maintain a positive outlook with a consensus price target of $243.33.
CAH presents a compelling investment case driven by earnings growth and defensive healthcare distribution. However, risks include high debt levels, thin profit margins, and competitive pressures. The stock's valuation at a P/E of 36.26 may limit upside if growth moderates. Overall, the bullish analyst consensus and operational strength support a positive medium-term view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
